

# UC Santa Cruz

## UC Santa Cruz Previously Published Works

### Title

TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma.

### Permalink

<https://escholarship.org/uc/item/1nw2w97c>

### Journal

Science, 378(6620)

### Authors

Chun-On, Pattra  
Hinchie, Angela  
Beale, Holly  
et al.

### Publication Date

2022-11-11

### DOI

10.1126/science.abq0607

Peer reviewed



Published in final edited form as:

Science. 2022 November 11; 378(6620): 664–668. doi:10.1126/science.abq0607.

## TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma

Pattra Chun-on<sup>1,2,3</sup>, Angela M. Hinchie<sup>1</sup>, Holly C. Beale<sup>4,5</sup>, Agustin A. Gil Silva<sup>1</sup>, Elizabeth Rush<sup>6</sup>, Cindy Sander<sup>6</sup>, Carla J. Connelly<sup>8</sup>, Brittani K.N. Seynnaeve<sup>6,7</sup>, John M. Kirkwood<sup>6</sup>, Olena M. Vaske<sup>4,5</sup>, Carol W. Greider<sup>4,5,8,\*</sup>, Jonathan K. Alder<sup>1,\*</sup>

<sup>1</sup>Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, Division of Pulmonary, Allergy, and Critical Care Medicine; Pittsburgh, PA, USA.

<sup>2</sup>Environmental and Occupational Health Department, School of Public Health, University of Pittsburgh; Pittsburgh, PA, USA.

<sup>3</sup>Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy; Bangkok, Thailand.

<sup>4</sup>UC Santa Cruz, Genomics Institute, University of California, Santa Cruz; CA, USA.

<sup>5</sup>Department of Molecular, Cell and Developmental Biology, University of California, Santa Cruz; CA, USA.

<sup>6</sup>University of Pittsburgh Medical Center, Hillman Cancer Institute; Pittsburgh, PA, USA.

<sup>7</sup>Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

<sup>8</sup>Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine; Baltimore, MD, USA.

### Abstract

Overcoming replicative senescence is an essential step during oncogenesis and reactivation of *TERT* via promoter mutations is a common mechanism. *TERT* promoter mutations are acquired in ~75% of melanomas but are not sufficient to maintain telomeres, suggesting additional mutations

---

\*Corresponding author. jalder@pitt.edu and cgreider@ucsc.edu.

Author contributions:

Conceptualization: CWG, JKA

Data curation: JKA, PC, HB

Formal analysis: JKA, PC, HB, OV

Methodology: PC, AMH, AAGS, ER, CS, CJC, HCB, OMB

Investigation: PC, BS, JMK, CWG, JKA, HCB, OMB

Visualization: PC, AMH, HCB

Resources: ER, CS, BS, JMK

Funding acquisition: CWG, JKA

Writing – original draft: PC, CWG, JKA

Writing – review & editing: All authors

All other authors have no conflicts of interest to declare.

Supplementary Materials

Materials and Methods

Figs. S1 to S8

References 26–39

are required. We identified a cluster of variants in the promoter of *ACD*, encoding the shelterin component TPP1. *ACD* promoter variants are present in ~5% of cutaneous melanoma and co-occur with *TERT* promoter mutations. The two most common somatic variants create or modify binding sites for ETS transcription factors, similar to mutations in the *TERT* promoter. The variants increase the expression of *TPP1* and function together with TERT to synergistically lengthen telomeres. Our findings suggest that *TPP1* promoter variants collaborate with *TERT* activation to enhance telomere maintenance and immortalization in melanoma.

### One-Sentence Summary:

TPP1 promoter mutations synergize with TERT activation to elongate telomeres in melanoma.

---

Escaping replicative senescence is an essential step of oncogenesis (1, 2). Telomere shortening limits the proliferative potential of cells and several mechanisms have been identified that permit tumor cells to extend telomeres and increase their replicative capacity (3–8). Somatic mutations in the *TERT* promoter are the most common identifiable mechanism in melanoma and are found in ~75% of cases (5, 9). TERT is the catalytic component of telomerase, the enzyme responsible for *de novo* telomere synthesis and maintenance of telomeres. *TERT* promoter mutations are not sufficient to immortalize some cell types and telomeres continue to shorten in nevi during the transition to melanoma despite acquisition of *TERT* promoter mutations (10). Therefore, while additional mutations are likely required to enable telomere elongation and immortalization, the genomic changes that potentially synergize with *TERT* promoter mutations to achieve sustained telomere maintenance remain unknown (10).

We sought to identify novel mechanisms of telomere maintenance in cancer cells by analyzing somatic mutations that occur in telomere-related genes. We focused our analysis on melanoma as individuals with germline variants in the *TERT* promoter predominantly develop this cancer (5). We examined somatic variants from telomere-related genes in melanoma from the International Cancer Genome Consortium (ICGC) (11). Mutations in TPP1 and POT1, components of the six-protein shelterin complex that coats telomeres, have been reported in familial melanoma (12–14) and we found numerous somatic variants among 749 melanomas samples analyzed (Fig. S1). We noted a cluster of recurrent somatic variants in a conserved region of *ACD*, the gene encoding TPP1 (which we refer to as the *TPP1* gene hereafter for clarity), that co-localize with histone marks typically associated with promoters (Fig 1A). *TPP1* has been reported to have two isoforms, TPP1-long (L) and -short (S), that differ by 86 amino acids in the N-terminus (15, 16). The cluster of variants was positioned such that they would be coding variants in TPP1-L and promoter variants in TPP1-S. To determine which isoform of TPP1 was expressed in melanoma, we examined RNA-seq data from 12 melanoma cell lines and 61 micro dissected nevi and melanoma samples (GSE153592 and GSE112509)(17, 18) and found that TPP1-S was the only isoform expressed (Fig. 1A and Fig. S2). To further validate this finding, we cloned the entire genomic region (3.5 kb including 895 base pairs upstream of the TPP1-S translational start site and 637 base pairs upstream of the TPP1-L translation start site and all exons and introns of both isoforms) of *TPP1* into a plasmid without an additional promoter and incorporated a C-terminal FLAG-tag. Immunofluorescent staining confirmed that the

C-terminally tagged TPP1 co-localized with TRF2 at telomeres (Fig. 1B). We generated cDNA expression constructs for TPP1-L, TPP1-S, and TPP1-L(M87A) which is incapable of expressing TPP1-S as controls (15). Western blot of cells expressing the entire genomic region with (TPP1<sub>pro</sub> – 108C>T and TPP1<sub>pro</sub> – 75C>T) and without (TPP1<sub>pro</sub> WT) the two most common variants showed that only TPP1-S was expressed in HEK293 and the melanocytic cell lines LOX and MEL624 (Fig. 1C). Together, these findings support that the cluster of variants we identified are localized to the promoter of TPP1-S. For clarity, we will refer to TPP1-S as TPP1 hereafter.

Previous studies have investigated the role of non-coding mutations in cancers including melanoma (19–21). Because the annotations of 5'-portion of *TPP1* have changed from coding to noncoding in recent years, (Fig. S2), the region we identified would not have been included as a promoter region in earlier studies. We tested if the proximal 200 base pairs upstream of the *TPP1* translational start site was significantly enriched for somatic variants by examining whole genome sequencing data from 305 patient-derived melanoma samples available from the ICGC and found that the *TPP1* proximal promoter was significantly enriched relative to 59,727 annotated promoters (FDR-corrected p-value 6.57e–14).

We next sought to determine the functional consequences of the somatic variants we identified in the promoter of *TPP1*. The two most common variants were C>T transitions located 75 and 108 base pairs upstream of the translational start site for TPP1. The –108 variant created the core binding sequence TTCC for E-twenty-six (ETS) family of transcription factors. The –75 variant was adjacent to an existing ETS site in the context of a sequence that is enriched for mutations in melanoma (21), created a novel TFIID binding site, and co-localized with the annotated transcriptional start site for the TPP1-S mRNA (Fig. 2 and S3). The identification of two recurrent promoter variants that created or modified ETS transcription factor binding sites bore remarkable similarity to putative activating mutations in the *TERT* promoter (5, 6), although the precise sequences created by the variants are distinct. We found *TPP1* was upregulated in several large databases of cancer gene expression including those with a high frequency of *TERT* promoter mutations (Fig. S4); however, there was insufficient data for the analysis of melanoma with *TPP1* promoter mutations specifically. To further characterize the *TPP1* promoter variant, we generated luciferase reporters of progressively smaller fragments of the TPP1 proximal promoter and found a 285 base pair fragment was sufficient for full basal transcriptional activity (Fig. S3E). Introduction of the –75 or –108 C>T promoter variants had little effect on luciferase expression in HEK293 cells but showed a small but significant increase in luciferase expression in two melanoma cell lines, LOX and MEL624 (Fig. 2A), suggesting that melanoma-specific ETS transcription factors are required for increased activity. RNA-seq data from 426 melanoma samples (11) showed that of 27 ETS family members, ETV5, ETS1, and ETV4 were the most abundantly expressed (Fig. S5). We confirmed this finding using quantitative PCR (qPCR) and western blotting on non-melanoma lines HeLa, BJ fibroblasts, and HEK293 and several melanoma cell lines and short-term primary cultures (Fig. 2B–C). Finally, we overexpressed ETV5, ETV4, or ETS1 in HEK293 cells and found all three robustly increased the activity of the TPP1 promoter only when the promoter variants were present (Fig. 2D). These data suggest that the *TPP1* promoter variants are activated by ETS transcription factors that are abundantly expressed in melanomas.

To determine the cellular consequences of increased TPP1 expression, we generated stable cell lines that overexpress TPP1 in telomerase positive HeLa cells. For completeness we also examined TPP1-L. We examined if cells stably expressing c-terminally tagged TPP1-S and TPP1-L altered telomere length in telomerase-expressing HeLa cells. Consistent with previous reports (15, 22), stable over-expression of TPP1-S led to considerable telomere lengthening, whereas TPP1-L caused telomere shortening (Fig. 3A). These data confirm that increased expression of TPP1 can lead to telomere lengthening in telomerase-expressing cells.

We next examined whether over-expression of TPP1 could extend the proliferative capacity of cells that express limiting amounts of telomerase. We expressed TPP1, TERT, or both in primary BJ fibroblasts, and monitored their proliferative capacity for 90 days (Fig. 3B–C). Control untransduced fibroblasts and fibroblasts transduced with TPP1 alone entered replicative senescence after about 40 days. In contrast, cells transduced with TERT and TERT+TPP1 bypassed senescence and were immortalized (Fig. 3B). These findings are consistent with previous reports that have demonstrated that TERT over-expression is sufficient to immortalize primary fibroblasts (23). We next examined telomere length in control and TPP1-transduced fibroblasts and found telomeres were very heterogeneous with a median of about 6 kb in length after 15 passages. Introduction of TERT caused telomere lengthening consistent with previous reports (23) and the co-expression of TERT and TPP1 together caused a synergistic effect resulting in significant telomere elongation (Fig 3D). These findings indicate that TERT and TPP1 overexpression is synergistic and lengthens telomeres more than TERT overexpression alone.

To determine whether the TPP1 promoter variants were sufficient to increase telomere addition, we introduced the two most common variant (–75C>T and –108C>T) into MEL624 and LOX cells using CRISPR/Cas9 (see supplementary methods) (Fig. S6). Six clones from MEL624 and LOX cells were obtained and sequence verified. We examined the expression of *TPP1* after modifying the endogenous promoter and found that introduction of either the –75 or –108 variants significantly increase expression of *TPP1* (Fig. 4A). The greater increase in expression levels of *TPP1* from the modified endogenous promoter (Fig. 4C) compared to the luciferase assay (Fig. 2A) suggest that additional factors may contribute to *TPP1* expression in melanoma. Telomeres are extremely long in MEL624 and LOX cells (>20 kb), and it is not possible to detect changes in length via a Southern blot. We therefore used fluorescence *in situ* hybridization (FISH) to detect a modified telomere sequence as a surrogate for *in vivo* telomerase activity as previously described (Fig. 4B) (24). We used a telomerase RNA encoding the variant telomere repeat, TTAGGT, which can be incorporated into telomeres and localized with a peptide nucleic acid fluorescent probe. Wild-type or genome-edited MEL624 or LOX cell lines with the most common promoter variants were co-transduced with lentiviruses that express the variant telomerase RNA and hTERT. Using FISH to examine the percentage of telomeres with variant repeats, we found cells that had a modified *TPP1* promoter incorporated significantly more TTAGGT variant repeat sequences on telomeres (Fig. 4C, D and Fig. S7). These findings suggest that TPP1 promoter mutations synergize with hTERT to increase telomere repeat addition in melanoma cells.

We next investigated the co-occurrence of somatic *TERT* and *TPP1* promoter mutation in cancer. *TPP1* promoter variants are found primarily in cancers of the skin but have been reported in several different cancer types (Fig. S8). The rationale for the disproportional number of variants in melanoma is unknown but may be related to the high mutation rate and reliance on telomerase activation in this cancer. In a dataset of deeply sequenced cutaneous melanomas (25), 139 samples were evaluated for the presence of the *TERT* and *TPP1* promoter variants. A large fraction (83%) carried a somatic variant in the *TERT* promoter, as previously reported (5, 9) and 8 samples carried a *TPP1* promoter variant (~6%). In all cases except one, the *TERT* and *TPP1* promoter variants were found together in the same tumor (Fig. 4E). However, due to limitations in current WGS data sets, additional studies using targeted resequencing will be required to determine the frequency of *TPP1* and *TERT* promoter mutations in cancers other than melanoma. We find that *TPP1* upregulation in the absence of telomerase expression is unlikely to influence telomere length or cellular immortality. Therefore, selection for *TPP1* promoter variants is most likely to occur subsequent to activation of telomerase (Fig 4E). Our data indicate that *TPP1* is one of the missing factors that collaborate with *TERT* promoter mutations to facilitate cellular immortalization in melanoma. Identifications of novel pathways that contribute to telomere lengthening and cellular immortalization may have both significant prognostic value and inform the development of possible treatments for patients with cancer and those with diseases of telomere shortening. Our findings further support that multiple non-coding mutations can cooperate to enable cellular immortalization and highlight the importance of understanding the contribution of non-coding variants to cancer.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments:

We would like to acknowledge the contributions of all patients that participated in the various studies reported here. We appreciate the samples provided by the Melanoma Center Biospecimen Repository (UPCI 96-99). We would also like to acknowledge C. Wongchokprasitti and M. Diekans for their assistance in bioinformatic analysis and data presentation. We also acknowledge thoughtful feedback from P. Opresko and T. Finkel on this manuscript.

## Funding:

National Institutes of Health grant R35CA209974 (CWG, JKA)

National Institutes of Health grant R01HL135062 (JKA)

Funding from HRH Princess Chulabhorn College of Medical Science to support Pattra Chun-on's graduate studies in Environmental and Occupational Health Science, School of Public Health, University of Pittsburgh

## Competing interests:

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

JMK reports advisory/consultancy roles with Amgen Inc., Ankyra Therapeutics, Applied Clinical Intelligence LLC, Axio Research LLC, Becker Pharmaceutical Consulting, Bristol Myers Squibb, Cancer Network, Checkmate Pharmaceuticals, DermTech, Fenix Group International, Harbour BioMed, Immunocore LLC, iOnctura, Istari Oncology, Magnolia Innovations LLC, Merck, Natera Inc, Novartis Pharmaceuticals, OncoCyte Corporation, OncoSec Medical Inc., PathAI Inc., Pfizer Inc., Replimune, Scopus BioPharma, SR One Capital Management,

Takeda Development Center Americas Inc., and Takeda Pharmaceutical Company Limited; and research grant/funding to their institution from Amgen Inc., Bristol Myers Squibb, Checkmate Pharmaceuticals, Harbour BioMed, Immvira Pharma Co., Immunocore LLC, Iovance Biotherapeutics, Novartis Pharmaceuticals, Takeda, and Verastem Inc.

## Data and materials availability:

All data and materials used in the analysis are available to any researcher for purposes of reproducing or extending our analysis. All data are available in the main text or the supplementary materials. Please contact Jonathan Alder (jalder@pitt.edu) to request any materials.


## References

1. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW, Specific association of human telomerase activity with immortal cells and cancer. *Science*. 266, 2011–2015 (1994). [PubMed: 7605428]
2. Hanahan D, Weinberg RA, Hallmarks of cancer: the next generation. *Cell*. 144, 646–674 (2011). [PubMed: 21376230]
3. Harley CB, Futcher AB, Greider CW, Telomeres shorten during ageing of human fibroblasts. *Nature*. 345, 458–460 (1990). [PubMed: 2342578]
4. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, DallaFavera R, Direct activation of TERT transcription by c-MYC. *Nat. Genet* 21, 220–224 (1999). [PubMed: 9988278]
5. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R, TERT promoter mutations in familial and sporadic melanoma. *Science*. 339, 959–961 (2013). [PubMed: 23348503]
6. Huang FW, Bielski CM, Rinne ML, Hahn WC, Sellers WR, Stegmeier F, Garraway LA, Kryukov GV, TERT promoter mutations and monoallelic activation of TERT in cancer. *Oncogenesis*. 4, e176 (2015).
7. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, Lichtenberg T, Hu J, Zhang J, Zheng S, Verhaak RGW, Systematic analysis of telomere length and somatic alterations in 31 cancer types. *Nat. Genet* 49, 349–357 (2017). [PubMed: 28135248]
8. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Fischer M, Telomerase activation by genomic rearrangements in high-risk neuroblastoma. *Nature*. 526, 700–704 (2015). [PubMed: 26466568]
9. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA, Highly recurrent TERT promoter mutations in human melanoma. *Science*. 339, 957–959 (2013). [PubMed: 23348506]
10. Chiba K, Lorbeer FK, Shain AH, McSwiggen DT, Schruf E, Oh A, Ryu J, Darzacq X, Bastian BC, Hockemeyer D, Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. *Science*. 357, 1416–1420 (2017). [PubMed: 28818973]
11. Zhang J, Bajari R, Andric D, Gerthoffert F, Lepsa A, Nahal-Bose H, Stein LD, Ferretti V, The international cancer genome consortium data portal. *Nat. Biotechnol* 37, 367–369 (2019). [PubMed: 30877282]
12. Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG, Liu JZ, Choi J, Adams DJ, POT1 loss-of-function variants predispose to familial melanoma. *Nat. Genet* 46, 478–481 (2014). [PubMed: 24686849]
13. Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K, Stark MS, Hayward NK, Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. *J Natl Cancer Inst*. 107 (2015), doi:10.1093/jnci/dju408.

14. Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fagnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, Avril MF, Caporaso NE, McMaster ML, Cullen M, Wang Z, Zhang X, NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, French Familial Melanoma Study Group, Bruno W, Pastorino L, Landi MT, Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. *Nat. Genet* 46, 482–486 (2014). [PubMed: 24686846]
15. Grill S, Bisht K, Tesmer VM, Shami AN, Hammoud SS, Nandakumar J, Two Separation-of-Function Isoforms of Human TPP1 Dictate Telomerase Regulation in Somatic and Germ Cells. *Cell Rep.* 27, 3511–3521.e7 (2019). [PubMed: 31216472]
16. Boyle JM, Hennick KM, Regalado SG, Vogan JM, Zhang X, Collins K, Hockemeyer D, Telomere length set point regulation in human pluripotent stem cells critically depends on the shelterin protein TPP1. *Mol. Biol. Cell* 31, 2583–2596 (2020). [PubMed: 32903138]
17. Motwani J, Rodger EJ, Stockwell PA, Baguley BC, Macaulay EC, Eccles MR, Genome-wide DNA methylation and RNA expression differences correlate with invasiveness in melanoma cell lines. *Epigenomics*. 13, 577–598 (2021). [PubMed: 33781093]
18. Kunz M, Löffler-Wirth H, Dannemann M, Willscher E, Doose G, Kelso J, Kottek T, Nickel B, Hopp L, Landsberg J, Hoffmann S, Tüting T, Zigrino P, Mauch C, Utikal J, Ziemer M, Schulze H-J, Hölzel M, Roesch A, Kneitz S, Schartl M, RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. *Oncogene*. 37, 6136–6151 (2018). [PubMed: 29995873]
19. Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, Hornshøj H, Hess JM, Juul RI, Lin Z, Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzós A, Herrmann C, Maruvka YE, Shen C, PCAWG Consortium, Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature*. 578, 102–111 (2020). [PubMed: 32025015]
20. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W, Genome-wide analysis of noncoding regulatory mutations in cancer. *Nat. Genet* 46, 1160–1165 (2014). [PubMed: 25261935]
21. Fredriksson NJ, Elliott K, Filges S, Van den Eynden J, Ståhlberg A, Larsson E, Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature. *PLoS Genet*. 13, e1006773 (2017). [PubMed: 28489852]
22. Nandakumar J, Bell CF, Weidenfeld I, Zaug AJ, Leinwand LA, Cech TR, The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. *Nature*. 492, 285–289 (2012). [PubMed: 23103865]
23. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE, Extension of life-span by introduction of telomerase into normal human cells. *Science*. 279, 349–352 (1998). [PubMed: 9454332]
24. Diolaiti ME, Cimini BA, Kageyama R, Charles FA, Stohr BA, In situ visualization of telomere elongation patterns in human cells. *Nucleic Acids Res.* 41, e176 (2013). [PubMed: 23963699]
25. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Mann GJ, Whole-genome landscapes of major melanoma subtypes. *Nature*. 545, 175–180 (2017). [PubMed: 28467829]
26. Cesare AJ, Heaphy CM, O’Sullivan RJ, *Curr. Protoc. Cytom*, in press, doi:10.1002/0471142956.cy1240s73.
27. Morrish TA, Greider CW, Short telomeres initiate telomere recombination in primary and tumor cells. *PLoS Genet*. 5, e1000357 (2009). [PubMed: 19180191]
28. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR, STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 29, 15–21 (2013). [PubMed: 23104886]
29. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D, The human genome browser at UCSC. *Genome Res*. 12, 996–1006 (2002). [PubMed: 12045153]
30. Raney BJ, Dreszer TR, Barber GP, Clawson H, Fujita PA, Wang T, Nguyen N, Paten B, Zweig AS, Karolchik D, Kent WJ, Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC Genome Browser. *Bioinformatics*. 30, 1003–1005 (2014). [PubMed: 24227676]




31. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, Wong MC, Maddren M, Fang R, Heitner SG, Lee BT, Barber GP, Harte RA, Diekhans M, Long JC, Wilder SP, Zweig AS, Karolchik D, Kuhn RM, Haussler D, Kent WJ, ENCODE data in the UCSC Genome Browser: year 5 update. *Nucleic Acids Res.* 41, D56–63 (2013). [PubMed: 23193274]
32. Frankish A, Diekhans M, Jungreis I, Lagarde J, Loveland JE, Mudge JM, Sisu C, Wright JC, Armstrong J, Barnes I, Berry A, Bignell A, Boix C, Carbonell Sala S, Cunningham F, Di Domenico T, Donaldson S, Fiddes IT, García Girón C, Gonzalez JM, Flicek P, GENCODE 2021. *Nucleic Acids Res.* 49, D916–D923 (2021). [PubMed: 33270111]
33. Soltis AR, Dalgard CL, Pollard HB, Wilkerson MD, MutEnricher: a flexible toolset for somatic mutation enrichment analysis of tumor whole genomes. *BMC Bioinformatics.* 21, 338 (2020). [PubMed: 32736515]
34. Park S-J, Yoon B-H, Kim S-K, Kim S-Y, GENT2: an updated gene expression database for normal and tumor tissues. *BMC Med. Genomics* 12, 101 (2019). [PubMed: 31296229]
35. Tang G, Cho M, Wang X, OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. *Nucleic Acids Res.* 50, D1334–D1339 (2022). [PubMed: 34718715]
36. Calvete O, Garcia-Pavia P, Domínguez F, Bougeard G, Kunze K, Braeuning A, Teule A, Lasa A, Ramón Y Cajal T, Llorca G, Fernández V, Lázaro C, Urioste M, Benitez J, The wide spectrum of POT1 gene variants correlates with multiple cancer types. *Eur. J. Hum. Genet* 25, 1278–1281 (2017). [PubMed: 28853721]
37. He H, Li W, Comiskey DF, Liyanarachchi S, Nieminen TT, Wang Y, DeLap KE, Brock P, de la Chapelle A, A Truncating Germline Mutation of TINF2 in Individuals with Thyroid Cancer or Melanoma Results in Longer Telomeres. *Thyroid.* 30, 204–213 (2020). [PubMed: 31928178]
38. Messeguer X, Escudero R, Farré D, Núñez O, Martínez J, Albà MM, PROMO: detection of known transcription regulatory elements using species-tailored searches. *Bioinformatics.* 18, 333–334 (2002). [PubMed: 11847087]
39. Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, Messeguer X, Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. *Nucleic Acids Res.* 31, 3651–3653 (2003). [PubMed: 12824386]




**Fig. 1. Identification of a cluster of somatic promoter variant in *TPPI*.**

(A) The genomic locus of the *ACD* gene is depicted from UCSC genome browser data with dark blue rectangles indicating the exon for TPP1-S and TPP1-L respectively. The red bars below the gene tract show the location of the somatic variants identified in the ICGC database with taller bars corresponding to the number of melanomas found with a specific variant. RNA-seq data (GSE153592) is shown above the gene tract in purple along with vertebrate conservation and H3K27 acetylation marks from multiple cell lines, indicating the location of likely regulatory regions. (B) HeLa stable cell lines expressing a C-terminally FLAG-tagged TPP1 were stained for the shelterin component TRF2 and the FLAG epitope. Colocalization of TPP1 with TRF2 suggest that the C-terminal FLAG-tag does not disrupt localization of TPP1 to the telomere. (C) Western blot of HEK293, LOX, and MEL624 cells transfected with plasmids encoding the cDNAs for TPP1-S and TPP1-L, and TPP1-L-M87A that is incapable of expressing TPP1-S together with plasmids expressing the entire genomic locus of TPP1 with and without the most common promoter variants.




**Fig. 2. ETS transcription factors activate the variant TPP1 promoter.**

(A) Luciferase assays were performed with a 285 base pair fragment of the TPP1 proximal promoter in melanoma and non-melanoma cell lines. The TPP1 promoter variants had little effect on the transcriptional activity in non-melanoma cells lines (HEK293), but increased reporter activity in two melanoma derived lines. (B) Quantitative PCR examining the levels of three ETS transcription factor family members in non-melanoma (HeLa, HEK293, and BJ fibroblast; n=3) and melanoma cell lines (MEL624 and LOX) and short-term primary cultures (n=6–7). Medians are shown and groups were compared using Mann-Whitney test. (C) Western blot showing high expression of ETS transcription factors in LOX melanoma and MEL624 lines. (D) Luciferase assays comparing activity of the TPP1 promoter reporter in the presence of three transfected ETS transcription factors in HEK293 cells. Cells were co-transfected with a pGL4 reporter and pCDNA3.1 expression plasmid with one of the three ETS transcription factors. Mean and standard deviation are shown from at least three independent experiments in (A) and (D) and groups were compared with a one-way ANOVA followed by Tukey’s multiple comparison test for pairwise comparisons. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, and \*\*\*\*P < 0.0001.



**Fig. 3. TPP1-S overexpression causes telomere lengthening and is synergistic with TERT overexpression.**

(A) Southern blot of telomeres in HeLa cell lines that stably expressed TPP1-S or TPP1-L for 90 days. Two independent clones of each are shown. P – parental cell line that was used to establish each of the modified clones. (B) Growth curves of cumulative population doublings of BJ fibroblasts expressing TPP1-S or TERT (average of 3 independent transduction for each group). (C) Western blot showing expression of each of the transgenes in cells collected from (B). (D) Southern blot of telomere lengths of BJ fibroblasts in (B) 15 passages after transduction showing synergistic telomere lengthening in cells exogenously overexpressing TPP1 and TERT.



**Fig. 4. TPP1 promoter mutations increase expression of the endogenous transcript and co-occur with TERT promoter mutations.**

(A) Quantitative PCR of *TPP1* expression following introduction of promoter mutations in LOX and MEL624 cells. Labels below the graph indicate the presumed zygosity based on sequencing. The media is shown from three independent measurements from each clone and groups were compared using one-way ANOVA followed by Dunnett's multiple comparison test. (B) Schematic of the experimental approach to measure telomerase activity in genetically modified cells. Cells are transduced with a *TERT*-expressing lentivirus to increase the rate of variant telomere incorporation. Following introduction of the mutant telomerase RNA (encoding TTAGGT), cells are passaged and the canonical and variant telomeres are quantitated. (C) Fluorescent in situ hybridization for the WT (TTAGGG; red) and variant (TTAGGT; green) in parental or genome edited MEL624 cells. Images

were taken 7 days after transduction with lentiviruses. (D) Quantitation of the fraction of telomeres that had both TTAGGG and TTAGGT signals from a single clone. Groups were compared using ANOVA with Dunnett's correction for multiple comparison. \*\* $P < 0.01$  and \*\*\*\* $P < 0.0001$ . (E) Proportion of cutaneous melanomas that had *TERT*, *TPP1*, or *TERT+TPP1* variants from Hayward et. al. (25) (F) Model of telomere length dynamics in melanoma progression. *TERT* promoter variants likely occur early and slow telomere attrition but are not sufficient to prevent telomere shortening (blue dashed lines in model). Telomere shortening continues until cells enter crisis (red dashed line). Additional mutations, like the *TPP1* promoter, are likely required to fully maintain telomeres and escape crisis (2<sup>nd</sup> hit).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript